-$0.22 EPS Expected for Vical Incorporated (VICL) This Quarter
Equities research analysts predict that Vical Incorporated (NASDAQ:VICL) will post earnings per share of ($0.22) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Vical’s earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.21). Vical posted earnings of ($0.27) per share in the same quarter last year, which indicates a positive year over year growth rate of 18.5%. The business is expected to report its next quarterly earnings results on Monday, October 22nd.
On average, analysts expect that Vical will report full year earnings of ($0.95) per share for the current year, with EPS estimates ranging from ($0.97) to ($0.92). For the next year, analysts expect that the firm will report earnings of ($1.02) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Vical.
Vical (NASDAQ:VICL) last posted its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.05. Vical had a negative net margin of 207.71% and a negative return on equity of 33.70%. The business had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $0.51 million.
Hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC bought a new position in Vical during the second quarter valued at $205,000. BlackRock Inc. increased its position in Vical by 20.0% during the second quarter. BlackRock Inc. now owns 394,320 shares of the biotechnology company’s stock valued at $453,000 after acquiring an additional 65,732 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in Vical by 13.9% during the second quarter. Renaissance Technologies LLC now owns 877,729 shares of the biotechnology company’s stock valued at $1,009,000 after acquiring an additional 107,100 shares during the last quarter. Institutional investors and hedge funds own 45.78% of the company’s stock.
VICL stock opened at $1.28 on Wednesday. Vical has a twelve month low of $1.02 and a twelve month high of $2.89. The firm has a market cap of $29.89 million, a price-to-earnings ratio of -1.27 and a beta of 0.64.
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection.
Recommended Story: S&P 500 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.